Posted by Michael Wonder on 10 Apr 2022
CMS made the wrong decision on Aduhelm. But there might be a silver lining.
9 April 2022 - CMS issued on Thursday its hotly debated final decision on whether to cover aducanumab (Aduhelm), the first FDA approved treatment for Alzheimer’s that slows the disease’s biological progression rather than just temporarily easing its symptoms.
We believe it made the wrong choice.
